Technologies

Title
Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Invention
The invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.

Background
Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.